Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment

Journal of Medicinal Chemistry

Volumn 50, Issue 26, 2007, Pages 6685-6691

  Chen, Liqiang ^a   Wilson, Daniel ^a   Jayaram, Hiremagalur N ^b   Pankiewicz, Krzysztof W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MYCOPHENOLIC HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMP DEHYDROGENASE; K562 CELLS; MYCOPHENOLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37349017604     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070864w     Document Type: Article

References (50)

1. Everts, S. Getting to the root of cancer. Chem. Eng. News 2007, 85, 28-29.
2. Kucia, M.; Ratajczak, M. Z. Stem cells as a two edged sword - from regeneration to tumor formation. J. Physiol. Pharmacol. 2006, 57 (7), 5-16.
3. Passegue, E. Hematopoietic stem cells, leukemic stem cells and chronic myelogenous leukemia. Cell Cycle 2005, 4, 266-268.
4. Bonnet, D. Normal and leukaemic stem cells. Br. J. Hamaetol. 2005, 130, 469-479.
5. Jordan, C. T. The leukemic stem cell. Best Pract. Res. Clin. Haematol. 2007, 20, 13-8.
6. Piccirillo, S. G.; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A. L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444, 761-765.
7. Deshpande, A. J.; Cusan, M.; Rawat, V. P.; Reuter, H.; Krause, A.; Pott, C.; Quintanilla-Martinez, L.; Kakadia, P.; Kuchenbauer, F.; Ahmed, F.; Delabesse, E.; Hahn, M.; Lichter, P.; Kneba, M.; Hiddemann, W.; Macintyre, E.; Mecucci, C.; Ludwig, W. D.; Humphries, R. K.; Bohlander, S. K.; Feuring-Buske, M.; Buske, C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 2006, 10, 363-374.
8. Yang, Z. J.; Wechsler-Reya, R. J. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007, 11, 3-5.
9. Jacquel, A.; Colosetti, P.; Grosso, S.; Belhacene, N.; Puissant, A.; Marchetti, S.; Breittmayer, J. P.; Auberger, P. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 2007, 26, 2445-2458.
10. Olah, E.; Csokay, B.; Prajda, N.; Kote-Jarai, Z.; Yeh, Y. A.; Weber, G. Molecular mechanisms in the antiproliferative action of Taxol and tiazofurin. Anticancer Res. 1996, 16, 2469-2477.
11. Grifantini, M. Tiazofurine ICN Pharmaceuticals. Curr. Opin. Invest. Drugs 2000, 1, 257-262.
12. Inai, K.; Tsutani, H.; Yamauchi, T.; Nakamura, T.; Ueda, T. Differentiation and reduction of intracellular GTP levels in HL-60 and U937 cells upon treatment with IMP dehydrogenase inhibitors. Adv. Exp. Med. Biol. 1998, 431, 549-553.
13. Gu, J. J.; Santiago, L.; Mitchell, B. S. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 2005, 105, 3270-3277.
14. Inai, K.; Tsutani, H.; Yamauchi, T.; Fukushima, T.; Iwasaki, H.; Imamura, S.; Wano, Y.; Nemoto, Y.; Naiki, H.; Ueda, T. Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil. Leuk. Res. 2000, 24, 761-768.
15. Floryk, D.; Tollaksen, S. L.; Giometti, C. S.; Huberman, E. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase. Cancer Res. 2004, 64, 9049-9056.
16. Floryk, D.; Huberman, E. Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity. Cancer Res. 2005, 65, 11588-11596.
17. Floryk, D.; Huberman, E. Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145. Cancer Lett. 2006, 231, 20-29.
18. Chong, C. R.; Qian, D. Z.; Pan, F.; Wei, Y.; Pili, R.; Sullivan, D. J., Jr.; Liu, J. O. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J. Med. Chem. 2006, 49, 2677-2680.
19. Takebe, N.; Cheng, X.; Wu, S.; Bauer, K.; Goloubeva, O. G.; Fenton, R. G.; Heyman, M.; Rapoport, A. P.; Badros, A.; Shaughnessy, J.; Ross, D.; Meisenberg, B.; Tricot, G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin. Cancer Res. 2004, 10, 8301-8308.
20. Takebe, N.; Cheng, X.; Fandy, T. E.; Srivastava, R. K.; Wu, S.; Shankar, S.; Bauer, K.; Shaughnessy, J.; Tricot, G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol. Cancer Ther. 2006, 5, 457-466.
21. Pankiewicz, K. W.; Lesiak-Watanabe, K. B.; Watanabe, K. A.; Patterson, S. E.; Jayaram, H. N.; Yalowitz, J. A.; Miller, M. D.; Seidman, M.; Majumdar, A.; Prehna, G.; Goldstein, B. M. Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J. Med. Chem. 2002, 45, 703-712.
22. Patterson, S. E.; Black, P. L.; Clark, J. L.; Risal, D.; Goldstein, B. M.; Jayaram, H. N.; Schinazi, R. F.; Pankiewicz, K. W. The Mechanism of Action and Antileukemic Activity of Bis(phosphonate) Analogue of Mycophenolic Adenine Dinucleotide (C2-MAD). An Alternative for Tiazofurin? In Developments in Nucleic Acids; Schinazi, R. F. L. D., Ed.; IHL Press: Arlingtion, MA, 2004.
23. Yalowitz, J. A.; Jayaram, H. N. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 2000, 20, 2329-2338.
24. Pankiewicz, K. W., Goldstein, B. M., Eds. Inosine Monophosphate Dehydrogenase: A Major Therapeutic Target; American Chemical Society: Washinghton, DC, 2003; Vol. 839.
25. Hedstrom, L.; Gan, L. IMP dehydrogenase; structural schizophrenia and an unusual base. Curr. Opin. Chem. Biol. 2006, 10, 520-525.
26. Mei, S.; Ho, A. D.; Mahlknecht, U. Role of histone deacetylase inhibitors in the treatment of cancer (review). Int. J. Oncol. 2004, 25, 1509-1519.
27. Kim, D. H.; Kim, M.; Kwon, H. J. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 2003, 36, 110-119.
28. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
29. Mahlknecht, U.; Hoelzer, D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 2000, 6, 623-644.
30. Kouraklis, G.; Theocharis, S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol. Rep. 2006, 15, 489-494.
31. Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; Sinclair, D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J. Med. Chem. 2005, 48, 7789-7795.
32. Yang, T.; Sauve, A. A. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. Am. Assoc. Pharm. Sci. J. 2006, 8, E632-E643.
33. Sauve, A. A.; Moir, R. D.; Schramm, V. L.; Willis, I. M. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol. Cell 2005, 17, 595-601.
34. Marks, P. A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26, 1351-1356.
35. Nimmanapalli, R.; Fuino, L.; Stobaugh, C.; Richon, V.; Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101, 3236-3239.
36. Yu, C. R.; Rahmani, M.; Almenara, J.; Subler, M.; Krystal, G.; Conrad, D.; Varticovski, L.; Dent, P.; Grant, S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl(+) human myeloid leukemia cells. Cancer Res. 2003, 63, 2118-2126.
37. Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Kramer, L. B.; Huang, M.; Jove, R.; Dent, P.; Grant, S. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 2005, 67, 1166-1176.
38. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; Richon, V.; Bhalla, K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 2006, 12, 5869-5878.
39. Franklin, T. J.; Jacobs, V.; Jones, G.; Ple, P. Human collorectal carcinoma cells in vitro as means to assess the metabolism of analogues of mycophenolic acid. Drug Metab. Dispos. 1997, 25, 367-374.
40. Sintchak, M. D.; Nimmesgern, E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000, 47, 163-184.
41. Jain, J.; Almquist, S. J.; Shlyakhter, D.; Harding, M. W. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J. Pharm. Sci. 2001, 90, 625-637.
42. Jain, J.; Almquist, S. J.; Heiser, A. D.; Shlyakhter, D.; Leon, E.; Memmott, C.; Moody, C. S.; Nimmesgern, E.; Decker, C. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′-monophosphate dehydrogenase inhibitor. J. Pharmacol. Exp. Ther. 2002, 302, 1272-1277.
43. Ishitsuka, K.; Hideshima, T.; Hamasaki, M.; Raje, N.; Kumar, S.; Podar, K.; Le Gouill, S.; Shiraishi, N.; Yasui, H.; Roccaro, A. M.; Tai, Y. Z.; Chauhan, D.; Fram, R.; Tamura, K.; Jain, J.; Anderson, K. C. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005, 24, 5888-5896.
44. Dhar, T. G.; Guo, J.; Shen, Z.; Pitts, W. J.; Gu, H. H.; Chen, B. C.; Zhao, R.; Bednarz, M. S.; Iwanowicz, E. J. A modified approach to 2-(N-aryl)-1,3-oxazoles: application to the synthesis of the IMPDH inhibitor BMS-337197 and analogues. Org. Lett. 2002, 4, 2091-2093.
45. Lee, Y. M.; Fujiwara, Y.; Ujita, K.; Nagatomo, M.; Ohta, H.; Shimizu, I. Syntheses of mycophenolic acid and its analogs by palladium methodology. Bull. Chem. Soc. Jpn. 2001, 74, 1437-1443.
46. Aoyama, T.; Shioiri, T. New methods and reagents in organic-synthesis. 8. Trimethylsilyldiazomethane, a new, stable, and safe reagent for the classical Arndt-Eistert synthesis. Tetrahedron Lett. 1980, 21, 4461-4462.
47. Jones, D. F.; Mills, S. D. Preparation and antitumor properties of analogs and derivatives of mycophenolic acid. J. Med. Chem. 1971, 14, 305-311.
48. Watterson, S. H.; Liu, C.; Dhar, T. G.; Gu, H. H.; Pitts, W. J.; Barrish, J. C.; Fleener, C. A.; Rouleau, K.; Sherbina, N. Z.; Hollenbaugh, D. L.; Iwanowicz, E. J. Novel amide-based inhibitors of inosine 5′-monophosphate dehydrogenase. Bioorg. Med. Chem. Lett. 2002, 12, 2879-2882.
49. Umejiego, N. N.; Li, C.; Riera, T.; Hedstrom, L.; Striepen, B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J. Biol. Chem. 2004, 279, 40320-40327.
50. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185, 269-286.